ASH 2021 Multiple Myeloma News
Advertisement
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Both are malignancies associated with significant immunoparesis.
Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease.
Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.
This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.
The findings report results from 24 months of maintenance therapy and were presented at the ASH Annual Meeting 2021.
Updates from this trial were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.